Clinical trial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment…
NCT00355082 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00355082 |
|---|---|
| Title | Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy |
| Official title | A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy, Partial |
| Intervention type | Drug |
| Interventions | lamotrigine, 300 mg/day, 250 mg/day |
| Enrollment | 226 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jul 21, 2006 |
| Last update posted | Jan 2, 2017 |
| Countries | Argentina, Chile, Costa Rica, Puerto Rico, Russia, South Korea, Ukraine, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: